• Home
  • About
    • Sonnet Overview
    • Sonnet Management Team
    • Sonnet CEO Corner
  • Technology
    • Overview
    • Platform
    • Publications
  • Pipeline
    • Overview
    • SON-1010
    • SON-1210
    • SON-080
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Sitemap

Sonnet BioTherapeutics, Inc. Sitemap

  • Home
  • About
    • Sonnet Overview
    • Sonnet Management Team
    • Sonnet CEO Corner
  • Technology
    • Overview
    • Platform
    • Publications
  • Pipeline
    • Pipeline Overview
    • SON-1010
    • SON-1210
    • SON-080
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Information
      • Overview
      • Management Team
      • Presentations
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Governance Documents
  • Contact
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2025 Sonnet BioTherapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap